Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin versus placebo or digital CBT-I for depression with sleep and circadian disturbance in young adults
ACTRN12624000017527Phase 3Recruiting
- Sponsor
- The University of Sydney
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melatonin in major depressive disorder (MDD) and Bipolar II disorder (BP-II), sponsored by The University of Sydney. Started Aug 2025; status: recruiting.
02
Drugs
melatonin
03
Conditions
major depressive disorder (MDD)Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on ACTRN12624000017527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000017527.